early-stage lung cancer
Conditions
Interventions
None listed
Sponsors
Nagoya City University West Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with non-small cell lung cancer diagnosed by histology or cytology, or those with a clinical diagnosis of lung cancer 2. Patients with clinical stage IA-II diagnosed by chest and abdominal CT, head MRI, or FDG-PET within 56 days (TNM classification: 2024, UICC 9th edition). 3. Males and females aged 20 years or older at the time of obtaining consent for treatment. 4. Patients who are able to maintain a stable position during irradiation. 5. Patients who are judged to be able to plan a treatment that does not exceed the dose limits for adjacent organs. 6. Patients who are deemed suitable for proton therapy by the Cancer Board. 7. Patients who have received an explanation of the treatment using a consent form and have given written consent for treatment.
Exclusion criteria
Exclusion criteria: 1. Pregnant or potentially pregnant patients 2. Patients whose wishes cannot be confirmed 3. Patients with active, refractory infections 4. Patients with psychiatric disorders or symptoms that make participation in this treatment protocol difficult 5. Patients with other serious complications (such as poorly controlled hypertension or diabetes, active gastrointestinal bleeding, etc.) 6. Patients who are deemed ineligible for this study by the researchers for medical, psychological, or other reasons other than those listed above.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 5 year overall survival | — |
Countries
Japan
Contacts
Public ContactIwata Hiromitsu
Nagoya City University West Medical Center Department of Radiation Oncology
Outcome results
None listed